![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/08/13/2929261/26135/en/Adial-Pharmaceuticals-Signs-Agreement-with-Boudicca-Dx-to-Advance-Regulatory-Strategy-for-Companion-Diagnostic-Genetic-Test-for-AD04.html
https://www.globenewswire.com/news-release/2024/08/07/2925971/26135/en/Adial-Pharmaceuticals-Announces-Last-Patient-Dosed-in-Pharmacokinetics-Study-of-AD04-for-the-Treatment-of-Alcohol-Use-Disorder.html
https://www.globenewswire.com/news-release/2024/07/31/2921852/26135/en/Adial-Pharmaceuticals-Files-New-Patent-Application-to-Protect-Core-Assets-and-Extend-IP-Exclusivity-on-Core-Technology-to-2044.html
https://www.globenewswire.com/news-release/2024/07/23/2917209/26135/en/Adial-Pharmaceuticals-Advances-to-Second-Cohort-in-Pharmacokinetics-Study-of-AD04-for-the-Treatment-of-Alcohol-Use-Disorder.html
https://www.globenewswire.com/news-release/2024/06/20/2901669/26135/en/Adial-Pharmaceuticals-Announces-Publication-in-Leading-Peer-Reviewed-Journal-Supporting-the-Potential-Efficacy-of-AD04-as-a-Precision-Medicine-for-the-Treatment-of-Alcohol-Use-Diso.html
https://www.globenewswire.com/news-release/2024/05/29/2889877/26135/en/Adial-CEO-to-Present-at-the-Spring-MicroCap-Rodeo-Conference-on-June-6th.html
https://www.globenewswire.com/news-release/2024/05/15/2882424/26135/en/Adial-Pharmaceuticals-Reports-First-Quarter-2024-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com/news-release/2024/04/22/2866860/26135/en/Adial-Pharmaceuticals-Granted-Key-Patent-from-the-United-States-Patent-and-Trademark-Office.html
https://www.globenewswire.com/news-release/2024/04/10/2860731/26135/en/Adial-Pharmaceuticals-Announces-Peer-Reviewed-Publication-Highlighting-Promising-Safety-Data-and-High-Patient-Compliance-in-a-Clinical-Trial-of-AD04-as-a-Potential-Treatment-for-Al.html
https://www.globenewswire.com/news-release/2024/04/02/2855951/26135/en/Adial-Pharmaceuticals-Reports-2023-Fiscal-Year-Financial-Results-and-Provides-Business-Update.html